KIORA PHARMACEUTICALS INC

In May 2026, Brian M. Strem, the Company's Chief Executive Officer, and Melissa Tosca, the Company's Chief Financial Officer, adopted pre-arranged “sell-to-cover” Rule 10b5-1 instructions, as defined in Rule 16a-1(f), to sell shares of common stock to the extent necessary to cover tax withholding on vesting of restricted stock units granted under company equity plans. Both plans are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The adoption date of both plans was May 12, 2026 and they will become effective on August 11, 2026 following the cooling off period. The plans will terminate on April 1, 2029. The maximum number of shares of common stock that can be sold pursuant to Dr. Strem's plan is 59,760, and the maximum number of shares of common stock that can be sold pursuant to Ms. Tosca's plan is 25,804. No other officers or directors, as defined in Rule 16a-1(f), adopted, modified orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement as defined in item 408 of Regulation S-K, during the period ended June 30, 2026.